People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Curemark Llc | — | Biotechnology | Series B | $81.4M | $17.0M | 2010 |
Kimball Duncan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kimball Duncan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew Heil | 1 | 3 |
| Klaus Kleinfeld | 1 | 3 |
| JENNIFER FRIST | 1 | 2 |
| Leigh Morgan | 1 | 1 |
| Afia Asamoah | 1 | 1 |
| Kimbell Duncan | 1 | 1 |
| JZANEEN LALANI | 1 | 1 |
| Eric Hermann | 1 | 1 |
| Joan Fallon | 1 | 1 |
| Justin Stebbing | 1 | 1 |
| Elisa Zinberg | 1 | 1 |
| Eric Herman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.